@elevii1's peptide claims for loose skin, fact-checked

What did @elevii1 actually say?

The creator made two distinct claims back to back: that tesamorelin targets "stubborn visceral belly fat" specifically, and that GHK-Cu "signals to your body to produce more collagen and skin repair" to prevent loose skin during rapid fat loss. Then they pitched stacking the two compounds together as a strategy for looking better through a body transformation. Worth noting: they called it "Tessa Merle and" throughout, which appears to be a pronunciation issue with tesamorelin. That matters because mispronouncing the compound name suggests a surface-level familiarity with what is actually an FDA-approved drug with a specific, narrow therapeutic indication. The claim that this "stack" is "super common" is also doing a lot of work without any supporting evidence. Common among whom? In what context? That framing deserves scrutiny.

Does the science back this up?

Tesamorelin has real data behind it, but the context matters enormously. The evidence is solid, but narrow. Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy, where it reduces visceral adipose tissue by stimulating growth hormone release. Falutz et al. (2007, NEJM) showed statistically significant reductions in visceral fat in that population. Claiming it targets "stubborn visceral belly fat" in a general weight loss context stretches that data considerably. As for GHK-Cu, there is legitimate in vitro and animal research suggesting it can upregulate collagen synthesis. Pickart et al. (2015, Journal of Aging Science) reviewed its role in skin remodeling. But robust human clinical trials showing topical or systemic GHK-Cu prevents loose skin during fat loss simply do not exist yet. The mechanism is biologically plausible. The specific application being described here is not proven.

What did they get wrong (or right)?

Credit where it is due: the basic mechanism descriptions are not wildly off. Tesamorelin does work through GHRH receptor activation and does reduce visceral fat in studied populations. GHK-Cu does have collagen-stimulating properties in laboratory settings. Those aren't invented claims. Where it goes wrong is the leap from "this compound does X in a specific population" to "stack these two for your body transformation." Tesamorelin is a prescription peptide with documented side effects including fluid retention, joint pain, and glucose dysregulation. Framing it casually as a "loose skin saver" stack ingredient glosses over all of that. The creator also never mentions that tesamorelin's visceral fat reduction data comes almost entirely from HIV-positive patients with a specific metabolic disorder, not from generally healthy people attempting fat loss. That omission is misleading, even if it wasn't intentional.

What should you actually know?

If you're considering either of these compounds, the regulatory and clinical picture is more complicated than a TikTok makes it sound. Tesamorelin is FDA-approved under the brand name Egrifta for a specific indication. Using it off-label for general fat loss puts you in territory where the evidence thins out quickly and the risk profile doesn't disappear. GHK-Cu research is genuinely interesting, particularly in wound healing and skin biology contexts, but systemic use for aesthetic loose skin prevention hasn't been validated in controlled human trials. The "stack" framing also raises a practical concern: combining compounds that both influence growth hormone pathways and collagen turnover without medical supervision is not a casual decision. Anyone interested in peptide therapy should be working with a licensed provider who can assess individual metabolic markers, not pulling compound combinations from social media. The biology here is real. The confidence in the protocol being described is not earned by the available evidence.